Drugs / Cripec Docetaxel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03712423 | Apr 2018 → Mar 2020 | neoplasm | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-06-22 | Cristal Therapeutics | Results Cristal Therapeutics’ proprietary CriPec® nanomedicine platform and promising preclinical data highlighted in three recent publications cristaltherapeutics.com ↗
The second publication of Hu et al. on CriPec ® docetaxel (the lead candidate of Cristal Therapeutics in Biomaterials) describes the complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-06-22 | Cristal Therapeutics | Cristal Therapeutics’ proprietary CriPec® nanomedicine platform and promising preclinical data highlighted in three recent publications cristaltherapeutics.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cripec Docetaxel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03712423 ↗ |